MARKET

NAMS

NAMS

NewAmsterdam Pharma Company N.V
NASDAQ
21.88
+0.22
+1.02%
Opening 15:51 04/30 EDT
OPEN
21.70
PREV CLOSE
21.66
HIGH
22.39
LOW
21.70
VOLUME
35.25K
TURNOVER
0
52 WEEK HIGH
26.35
52 WEEK LOW
5.63
MARKET CAP
1.95B
P/E (TTM)
-16.9415
1D
5D
1M
3M
1Y
5Y
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), NewAmsterdam Pharma Company (NAMS) and Humana (HUM)
TipRanks · 2d ago
Weekly Report: what happened at NAMS last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at NAMS last week (0415-0419)?
Weekly Report · 04/22 09:53
Weekly Report: what happened at NAMS last week (0408-0412)?
Weekly Report · 04/15 09:50
BRIEF-NewAmsterdam Pharma Enrolls Over 9,000 Patients In Late-Stage Global Cardiovascular Outcome Trial
NewAmsterdam Pharma Enrolls Over 9,000 Patients In Late-Stage Global Cardiovascular Outcome Trial. Company says trial will evaluate the effect of ibuprofen on patients with a cardiovascular disease. NewAmsterdam is a subsidiary of Amsterdam Pharma Company NV.
Reuters · 04/09 13:41
NEWAMSTERDAM PHARMA: WITH PREVAIL CVOT ENROLLMENT TARGET MET, TOPLINE DATA FROM BROOKLYN & BROADWAY EXPECTED IN Q3, Q4 2024, AND TANDEM IN Q1 2025
Reuters · 04/09 12:00
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. Has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial. The company is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.
Barchart · 04/09 07:00
Weekly Report: what happened at NAMS last week (0401-0405)?
Weekly Report · 04/08 09:51
More
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Webull offers NewAmsterdam Pharma Company NV stock information, including NASDAQ: NAMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NAMS stock methods without spending real money on the virtual paper trading platform.